CIK 0001425205
- Accelerated filer
IOVANCE BIOTHERAPEUTICS, INC.
Sign in to watch- Ticker
- IOVA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 753254381
- Phone
- +1 650-260-7120
- Business address
- 825 INDUSTRIAL ROAD, 4TH FLOOR, SAN CARLOS, CA, 94070
- Former names
- Lion Biotechnologies, Inc., Genesis Biopharma, Inc, FREIGHT MANAGEMENT CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 99 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-06-29 | WEISER MICHAEL Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2021-06-29 | MCPEAK MERRILL A Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2021-06-29 | Maynard Ryan D Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2021-06-29 | Dukes Iain D. Director | Grant or award · Stock Option (right to buy) | +70,000 | 70,000 | ||
| 2021-06-29 | Countouriotis Athena Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2021-06-14 | Bellemin Jean-Marc Chief Financial Officer | Grant or award · Restricted Stock Units | +37,700 | 37,700 | ||
| 2021-06-14 | GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | Grant or award · Restricted Stock Units | +39,380 | 39,380 | ||
| 2021-06-14 | BILINSKY IGOR Chief Operating Officer | Grant or award · Restricted Stock Units | +37,700 | 37,700 | ||
| 2021-06-14 | Vogt Frederick G Interim CEO & General Counsel | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2021-06-14 | Vogt Frederick G Interim CEO & General Counsel | Grant or award · Stock Option (right to buy) | +73,900 | 73,900 | ||
| 2021-03-15 | BILINSKY IGOR Chief Operating Officer | Grant or award · Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2021-01-04 | Swartzburg Michael Vice President, Finance (PAO) | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2021-01-04 | Fardis Maria President and CEO | Grant or award · Stock Option (right to buy) | +250,000 | 250,000 | ||
| 2021-01-04 | GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2021-01-04 | Vogt Frederick G General Counsel | Grant or award · Stock Option (right to buy) | +175,000 | 175,000 | ||
| 2020-12-14 | Bellemin Jean-Marc Chief Financial Officer | Grant or award · Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2020-06-08 | Dukes Iain D. Director | Grant or award · Stock Option (right to buy) | +70,000 | 70,000 | ||
| 2020-06-08 | MCPEAK MERRILL A Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2020-06-08 | WEISER MICHAEL Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2020-06-08 | Maynard Ryan D Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 |
Page 22 of 23 · 446 trades